Jasmine Singh Sukumar
Department of Breast Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2016 | University of Missouri-Kansas City, Kansas City, MO, USA, MD, BA/MD |
Postgraduate Training
| 2021-2022 | Postdoctoral Fellow, The Ohio State University and James Comprehensive Cancer Center, Columbus, OH |
| 2020-2021 | Clinical Fellowship, Breast Cancer Fellowship, The Ohio State University and James Comprehensive Cancer Center, Columbus, OH |
| 2019-2021 | Clinical Fellowship, Medical Oncology, The Ohio State University and James Comprehensive Cancer Center, Columbus, OH |
| 2016-2019 | Clinical Residency, Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX |
Board Certifications
| 2021 | Medical Oncology |
| 2019 | ABIM Internal Medicine |
Experience & Service
Institutional Committee Activities
Member, MD Anderson Breast Medical Oncology Survivorship and Database Working Group, 2022 - Present
Member, MD Anderson Survivorship Research Advisory Workgroup, 2022 - Present
Honors & Awards
| 2024 - 2025 | The MD Anderson Center for Energy Balance in Cancer Prevention and Survivorship Supplemental Funding Award, MD Anderson |
| 2024 - Present | The Robert A. Winn Diversity in Clinical Trials: Career Development Award |
| 2022 - Present | ASCO Conquer Cancer Young Investigator Award, ASCO |
| 2021 - 2022 | Pelotonia Post Doctoral Fellowship Award, The Ohio State University |
| 2021 - Present | Alliance Cancer Control Program Pilot Project Award |
| 2021 - 2022 | Transdisciplinary Research in Energetics and Cancer (TREC) Training Workshop, NIH |
| 2020 - 2021 | FDA-AACR Oncology Educational Fellowship, FDA-AACR |
| 2017 | Foster Fellow Research Grant, UT Southwestern Medical Center |
| 2013 | Sarah Morrison Student Research Grant, University of Missouri Kansas City |
Selected Publications
Peer-Reviewed Articles
- Sukumar JS, Sardesai S, Ni A, Williams N, Johnson K, Quiroga D, Ramaswamy B, Wesolowski R, Cherian M, Stover DG, Gatti-Mays M, Pariser A, Sudheendra P, George MA, Lustberg M. Real-world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer. Cancer Med 13(12):e7317, 2024. PMID: 38895891.
- Dennett AM, Hirko KA, Porter KJ, Loh KP, Liao Y, Yang L, Arem H, Sukumar JS, Salerno EA. Embedding lifestyle interventions into cancer care: has telehealth narrowed the equity gap?. J Natl Cancer Inst Monogr(61):133-139, 2023. PMID: 37139972.
- Stevens CJ, Liao Y, Chen M, Heredia NI, Arem H, Sukumar J, Joffe L, Schmitz KH, Mama SK. Linking social and built environmental factors to leisure-time physical activity in rural cancer survivors. J Natl Cancer Inst Monogr(61):125-132, 2023. PMID: 37139981.
- Johnson KC, Grimm M, Sukumar J, Schnell PM, Park KU, Stover DG, Jhawar SR, Gatti-Mays M, Wesolowski R, Williams N, Sardesai S, Pariser A, Sudheendra P, Tozbikian G, Ramaswamy B, Doto D, Cherian MA. Survival outcomes seen with neoadjuvant chemotherapy in the management of locally advanced inflammatory breast cancer (IBC) versus matched controls. Breast:103591, 2023. e-Pub 2023. PMID: 37871527.
- Sukumar JS, Vaughn JE, Tegge A, Sardesai S, Lustberg M, Stein J. Delay Discounting as a Potential Therapeutic Target for Weight Loss in Breast Cancer Survivors. Cancers (Basel) 14(5), 2022. e-Pub 2022. PMID: 35267441.
- Sukumar JS, Quiroga D, Kassem M, Grimm M, Shinde NV, Appiah L, Palettas M, Stephens J, Gatti-Mays ME, Pariser A, Cherian M, Stover DG, Williams N, Van Deusen J, Wesolowski R, Lustberg M, Ramaswamy B, Sardesai S. Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer. Breast Cancer Res Treat 190(2):183-188, 2021. e-Pub 2021. PMID: 34498153.
- Sukumar J, Kassem M, Agnese D, Pilarski R, Ramaswamy B, Sweet K, Sardesai S. Concurrent germline BRCA1, BRCA2, and CHEK2 pathogenic variants in hereditary breast cancer: a case series. Breast Cancer Res Treat 186(2):569-575, 2021. e-Pub 2021. PMID: 33507482.
- Sukumar J, Gast K, Quiroga D, Lustberg M, Williams N. Triple-negative breast cancer: promising prognostic biomarkers currently in development. Expert Rev Anticancer Ther 21(2):135-148, 2021. PMID: 33198517.
- Sardesai S, Sukumar J, Kassem M, Palettas M, Stephens J, Morgan E, Addison D, Baliga R, Stover DG, VanDeusen J, Williams N, Cherian M, Lustberg M, Wesolowski R, Ramaswamy B. Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer. Cardiooncology 6(1):26, 2020. e-Pub 2020. PMID: 33292843.
- Singh J, Merrill ED, Sandesara PB, Schoeneberg L, Dai H, Raghuveer G. Vitamin D, Low-Grade Inflammation and Cardiovascular Risk in Young Children: A Pilot Study. Pediatr Cardiol 36(7):1338-43, 2015. e-Pub 2015. PMID: 25832850.
- Jayan A, Sukumar JS, Fangman B, Patel T, Raghavendra A, Liu D, Rauch R, Basen-Engquist K, Tripathy D, Barcenas C.. Real-World Immune-related Adverse Effects in Patients with Early Triple Negative Breast Cancer who Received Pembrolizumab. JCO Oncology Practice.
Other Articles
- Sukumar J, Chavez Mac Gregor M. POSITIVE: Pregnancy after breast cancer should be supported for many, but not all. NEJM Group Clinical Updates.
Grant & Contract Support
| Date: | 2024 - 2026 |
| Title: | |
| Funding Source: | Bristol Myers Squibb Foundation and American Association of Cancer Research (AACR) |
| Role: | Principal Investigator |
| ID: | The Robert A. Winn Diversity in Clinical Trials: Career Development Award |
| Date: | 2024 - 2025 |
| Title: | The MD Anderson Center for Energy Balance in Cancer Prevention and Survivorship Supplemental Funding Award |
| Funding Source: | Cancer Prevention and Survivorship Supplemental Funding Award |
| Role: | Principal Investigator |
| ID: | The MD Anderson Center for Energy Balance in Cancer Prevention and Survivorship Supplemental Funding Award |
| Date: | 2024 - 2026 |
| Title: | Title: Association Between BMI/Body Composition and Clinical Outcomes with Immune Checkpoint Inhibitors in Triple Negative Breast Cancer |
| Funding Source: | MD Anderson Cancer Center Institutional Research Grant |
| Role: | Principal Investigator |
| Date: | 2022 - Present |
| Title: | ASCO Conquer Cancer Young Investigator Award |
| Funding Source: | American Society of Clinical Oncology (ASCO) |
| Role: | Principal Investigator |
| Date: | 2021 - 2022 |
| Title: | Pelotonia Postdoctoral Fellowship Award |
| Funding Source: | The Ohio State University |
| Role: | Principal Investigator |
| Date: | 2021 - Present |
| Title: | Alliance Cancer Control Program Pilot Project Award |
| Funding Source: | Alliance For Clinical Trials in Oncology |
| Role: | Co-Investigator |
Patient Reviews
CV information above last modified August 29, 2024